I toyed with the idea of getting back in around $6, but didn't pull the trigger. Congratulations to all honest longs.
Now, about those ROP profits. I guess $11 million is it and Insmed has no interest in reviving iPlex at this point.
You are correct about IPLEX as it pertains to ROP and about reviving it in the near term. INSM still holds the IP for IPLEX for other potential indications.
"INSM still holds the IP for IPLEX for other potential indications."
...except to the extent that such rights are owned by Roche/Genentech/Ipsen until 2018.